We are building biological artificial superintelligence
Building the AI scientist
Pioneering Biological Artificial SuperIntelligence
Understanding complex biology has outgrown the limits of human intelligence.
Today's drug R&D is siloed, slow and costly. Fragmented tools, disconnected workflows and expensive trials keep 90% of new drugs from ever reaching patients.
There's too much biological and clinical data, and no clear signal on what to analyse next.
To advance the treatments patients are still waiting for, healthcare needs a new paradigm: one where AI does science, not just supports it.
This is why we built K Pro.
Today, K Pro brings together biological LLMs, multimodal patient data and specialized biomedical skills into one AI Scientist, built to make drug discovery smarter and faster.
Over the past 10 years, we’ve built trusted partnerships across the biopharma ecosystem, working with over 100 leading academic hospitals and 8 of the top 10 pharma companies.
Today, that experience is brought together in a single AI Scientist: K Pro.
Our ambition goes further still.
We're working towards biological artificial superintelligence: an autonomous, self-improving AI Scientist that exceeds human performance across every life science domain, and is capable of running large parts of drug discovery on its own.
Trusted Expertise
Built on a decade of medical and biopharma expertise
Owkin is founder-led by Thomas Clozel, M.D. (Founder & CEO, medical & scientific) and Pascal Weinberger (Co-CEO, technology & product), with a 175 team spanning medicine, data science, frontier AI and biotech. We're advised by a Scientific Advisory Board chaired by Miriam Merad, M.D., Ph.D. (Mount Sinai), alongside leading experts across AI and oncology.
Ten years of relationships with pharmaceutical companies and hospitals have built the trust this vision depends on.
The path to autonomy
K Pro supports pipeline decisions, target discovery, clinical trial optimization and business decisions across biopharma.
The AI Scientist extends into hospitals as well as biopharma, generating owned IP alongside platform intelligence.
An AI Scientist operating at full reach across biopharma and hospitals, holding its own IP portfolio, and designing the majority of new drugs.
Owkin's AI Scientist
K Pro is built differently
Many AI systems in life sciences today are designed as copilots or focused on specific parts of the drug discovery process, from target identification to molecular design.
Owkin's AI Scientist, K Pro is designed to continuously learn, reason, and improve across the full drug development lifecycle by connecting biological understanding, patient data, and decision-making in one system.
3M characterised patients across an 840-institution hospital network, not just public datasets.
Our organoid and chemistry lab validates AI-generated hypotheses at the bench, closing the loop between dry lab and wet lab.
We work across discovery, development and care, including direct deployment into hospital tumor boards.
K Pro reasons through frontier models, including Claude, alongside Owkin's own proprietary biological foundation models and tools.
Learn more about what we do
Get answers in minutes, not hours, with the AI agent for biology, powered by multimodal patient data.
K Pro is trained and powered by the largest multimodal patient data network in the world.
This is how we deliver real-world impact to patients at a speed never seen before.
Contact our team
Whether you're interested in exploring a partnership, are interested in a one-to-one, or simply have a question, we'd love to hear from you.
Product updates, use cases, and insights to get more from K Pro.